{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:36:03Z","timestamp":1775284563905,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.cardfail.2006.02.013","type":"journal-article","created":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T18:34:40Z","timestamp":1149791680000},"page":"375-380","source":"Crossref","is-referenced-by-count":55,"title":["The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT)"],"prefix":"10.1016","volume":"12","author":[{"given":"Serge","family":"Masson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Barlera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Judd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Salio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perticone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Tognoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay N.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2006.02.013_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1358863X9700200106","article-title":"The endothelin system in cardiovascular physiology and pathophysiology","volume":"2","author":"Parris","year":"1997","journal-title":"Vasc Med"},{"key":"10.1016\/j.cardfail.2006.02.013_bib2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.CIR.85.2.510","article-title":"Elevated endothelin-1 in heart failure and loss of normal response to postural changes","volume":"85","author":"Stewart","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0002-9149(93)90543-L","article-title":"Plasma big endothelin-1 concentration in congestive heart failure patients with or without heart failure","volume":"71","author":"Pacher","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/01.CIR.89.4.1580","article-title":"Endothelin in human congestive heart failure","volume":"89","author":"Wei","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib6","first-page":"S95","article-title":"Multicentre, double-blind, placebo-controlled study of long-term endothelial blockade with bosentan in chronic heart failure: results of the REACH trial (abstract)","volume":"20","author":"Packer","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2006.02.013_bib7","first-page":"612","article-title":"Effects of enrasentan, a non selective endothelin receptor antagonist, in class II to III heart failure: results of the Enrasentan Cooperative Randomized (ENCOR) Evaluation","volume":"38","author":"Abraham","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib8","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2006.02.013_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0002-9149(99)80231-8","article-title":"Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure","volume":"76","author":"Tsutamoto","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/oxfordjournals.eurheartj.a015228","article-title":"Prognostic value of plasma endothelin-1 in patients with chronic heart failure","volume":"18","author":"Pousset","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2006.02.013_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1054\/jcaf.2000.8833","article-title":"Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure","volume":"6","author":"Selvais","year":"2000","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.cardfail.2006.02.013_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0002-9149(00)00957-7","article-title":"Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure","volume":"86","author":"Isnard","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib14","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0735-1097(00)00912-8","article-title":"High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors fro morbidity and morbidity in patients with congestive heart failure","volume":"36","author":"Maeda","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cardfail.2004.04.001","article-title":"Superiority of Big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study","volume":"10","author":"Van Beneden","year":"2004","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.cardfail.2006.02.013_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0735-1097(95)00520-X","article-title":"Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure","volume":"27","author":"Pacher","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/euhj.2001.3115","article-title":"Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure","volume":"23","author":"Hulsmann","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2006.02.013_bib18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1053-2498(02)00560-0","article-title":"Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period","volume":"22","author":"Berger","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2006.02.013_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.healun.2003.07.023","article-title":"Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure","volume":"23","author":"Gwechenberger","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2006.02.013_bib20","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2006.02.013_bib21","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2006.02.013_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/clinchem\/44.2.239","article-title":"Direct enzyme immunometric measurement of plasma big endothelin-1 concentrations and correlation with indicators of left ventricular function","volume":"44","author":"Haug","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.cardfail.2006.02.013_bib24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/01.CIR.98.16.1684","article-title":"Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction","volume":"98","author":"Dupuis","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cardiores.2004.03.016","article-title":"Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases synthesis and secretion of endothelin-1","volume":"63","author":"Von Lueder","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2006.02.013_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cardfail.2004.01.008","article-title":"Reduced pulmonary clearance of endothelin in congestive heart failure: a marker of secondary pulmonary hypertension","volume":"10","author":"Staniloae","year":"2004","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.cardfail.2006.02.013_bib27","first-page":"H1141","article-title":"Increased endothelin-1 production in patients with chronic heart failure","volume":"286","author":"Parker","year":"2004","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/01.CIR.102.10.1132","article-title":"Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure. Acute effects of vasodilator therapy","volume":"102","author":"Stangl","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/01.HYP.35.3.726","article-title":"ETB receptor blockade potentiates the pressor response to Big endothelin-1 but not Big endothelin-2 in the anesthetized rabbit","volume":"35","author":"Gratton","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2006.02.013_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0014-2999(90)90064-D","article-title":"Opposite effects of endothelin-1 and Big-endothelin-(1\u201339) on renal function in rats","volume":"182","author":"Hoffman","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/01.HYP.35.3.732","article-title":"Mechanisms of Big endothelin-1-induced diuresis and natriuresis. Role of ETB receptors","volume":"35","author":"Hoffman","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2006.02.013_bib32","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1161\/01.CIR.96.9.3053","article-title":"Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes. Acute effects of mixed ETA\/ETB and AT1 receptor antagonists in vivo and in vitro","volume":"96","author":"Magga","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2006.02.013_bib33","first-page":"H2678","article-title":"AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria","volume":"273","author":"Bruneau","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cardfail.2006.02.013_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1054\/jcaf.2003.39","article-title":"Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure","volume":"9","author":"Kinugawa","year":"2003","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.cardfail.2006.02.013_bib35","first-page":"282","article-title":"Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry","volume":"1","author":"Masson","year":"2000","journal-title":"Ital Heart J"},{"key":"10.1016\/j.cardfail.2006.02.013_bib36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","article-title":"Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"149","author":"Maggioni","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2006.02.013_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0167-0115(94)00119-I","article-title":"Metabolism of Big endothelin-1 (1\u201338) and (22\u201338) in the human circulation in relation to production of endothelin-1 (1\u201321)","volume":"55","author":"Hems\u00e9n","year":"1995","journal-title":"Regul Peptides"},{"key":"10.1016\/j.cardfail.2006.02.013_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004872-200018030-00006","article-title":"Receptor- and non-receptor-mediated clearance of big endothelin-1 and endothelin-1: differential effects of acute and chronic ETA receptor blockade","volume":"18","author":"Burkhardt","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.cardfail.2006.02.013_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2006.02.013_bib40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916406001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916406001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T10:17:47Z","timestamp":1586945867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916406001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S1071916406001333"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2006.02.013","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}